Hong Kong-based life sciences venture capital (VC) firm Delos Capital has reached the first closing of its Fund III at $300 million with support from investors across the US and Greater China.
In a statement on Tuesday, Delos Capital said that it completed the first closing after only six months of fundraising with all existing limited partners (LPs) in the predecessor Fund II re-upping or upsizing their positions in the new vehicle.
